Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 1,801–1,900 of 10,906
Akache, B., Renner, T. M., Tran, A., Deschatelets, L., Dudani, R., Harrison, B. A., Duque, D., Haukenfrers, J., Rossotti, M. A., Gaudreault, F., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01363-7 · Cited by 47
Little, J. S., Tandon, M., Hong, J., Nadeem, O., Sperling, A. S., Raje, N. S., Munshi, N. C., Frigault, M. J., Barmettler, S., & Hammond, S. P. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010524 · Cited by 50
Risk of death following COVID-19 vaccination or positive SARS-CoV-2 test in young people in England
Nafilyan, V., Bermingham, C. R., Ward, I. L., Morgan, J., Zaccardi, F., Khunti, K., Stanborough, J., Banerjee, A., & Doidge, J. (2023) · Nature Communications · doi:10.1038/s41467-023-36494-0 · Cited by 54
Lu, X., Hosono, Y., Nagae, M., Ishizuka, S., Ishikawa, E., Motooka, D., Ozaki, Y., Sax, N., Maeda, Y., Kato, Y., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20211327 · Cited by 46
Chen, L., Qu, J., Kalyani, F. S., Zhang, Q., Fan, L., Fang, Y., Li, Y., & Xiang, C. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04096-y · Cited by 51
Oktay, E., Alem, F., Hernandez, K. R., Girgis, M. J., Green, C. M., Mathur, D., Medintz, I. L., Narayanan, A., & Veneziano, R. (2023) · Communications Biology · doi:10.1038/s42003-023-04689-2 · Cited by 47
In Vitro Lung Models and Their Application to Study SARS-CoV-2 Pathogenesis and Disease
Heinen, N., Klöhn, M., Steinmann, E., & Pfaender, S. (2021) · Viruses · doi:10.3390/v13050792 · Cited by 46
DiRago, N. V., Li, M., Tom, T., Schupmann, W. D., Carrillo, Y., Carey, C., & Gaddis, S. M. (2021) · Journal of Urban Health · doi:10.1007/s11524-021-00589-0 · Cited by 49
Richterman, A. G., Meyerowitz, E. A., & Çevik, M. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab259 · Cited by 51
Immunologic Interplay Between HIV/AIDS and COVID-19: Adding Fuel to the Flames?
Augello, M., Bono, V., Rovito, R., Tincati, C., & Marchetti, G. C. (2023) · Current HIV/AIDS Reports · doi:10.1007/s11904-023-00647-z · Cited by 49
Vaccination and multiple sclerosis in the era of the COVID-19 pandemic
Monschein, T., Hartung, H., Zrzavy, T., Barnett, M. H., Boxberger, N., Berger, T., Chataway, J., Bar‐Or, A., Rommer, P. S., & Zettl, U. K. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-326839 · Cited by 47
Insights From Nanotechnology in COVID-19: Prevention, Detection, Therapy and Immunomodulation
Singh, P., Singh, D., Sa, P., Mohapatra, P., Khuntia, A., & Sahoo, S. K. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0004 · Cited by 50
Meyers, L. M., Gutiérrez, A. H., Boyle, C., Terry, F. E., McGonnigal, B., Salazar, A. Μ., Princiotta, M. F., Martin, W. D., Groot, A. S. D., & Moise, L. (2021) · npj Vaccines · doi:10.1038/s41541-021-00331-6 · Cited by 45
Opportunities and challenges of physiologically based pharmacokinetic modeling in drug delivery
Wang, W., & Ouyang, D. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.04.015 · Cited by 50
RNAdegformer: accurate prediction of mRNA degradation at nucleotide resolution with deep learning
He, S., Gao, B., Sabnis, R., & Sun, Q. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbac581 · Cited by 51
Salleh, M. Z., Norazmi, M. N., & Deris, Z. Z. (2022) · PeerJ · doi:10.7717/peerj.13083 · Cited by 51
Adverse reactions to COVID‐19 vaccines: A practical approach
Rutkowski, K., Mirakian, R. M., Till, S. J., Rutkowski, R., & Wagner, A. (2021) · Clinical & Experimental Allergy · doi:10.1111/cea.13880 · Cited by 44
Hernández–Díaz, S., Huybrechts, K. F., Chiu, Y., Yland, J. J., Bateman, B. T., & Hernán, M. Á. (2022) · Epidemiology · doi:10.1097/ede.0000000000001562 · Cited by 56
Outcome Reporting Bias in COVID-19 mRNA Vaccine Clinical Trials
Brown, R. B. (2021) · Medicina · doi:10.3390/medicina57030199 · Cited by 44
“The New England Journal of Medicine also published clinical trial data on safety and efficacy for the BNT162b2 vaccine [12] and the mRNA-1273 vaccine [13], but with no mention of absolute risk reduction measures.”
MethodKlemis, V., Schmidt, T., Schub, D., Mihm, J., Marx, S., Abu‐Omar, A., Ziegler, L., Hielscher, F., Guckelmus, C., Urschel, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32321-0 · Cited by 48
Hossain, M. E., Rana, M. J., Islam, S., Khan, M. A., Chakrobortty, S., Ema, N. S., & Bekun, F. V. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1968215 · Cited by 45
Rapaka, R. R., Hammershaimb, E. A., & Neuzil, K. M. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab213 · Cited by 49
Self-citationProfiles of current COVID-19 vaccines
Heinz, F. X., & Stiasny, K. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01835-w · Cited by 47
Rice, A., Verma, M. S., Shin, A., Zakin, L., Sieling, P. A., Tanaka, S., Balint, J. P., Dinkins, K., Adisetiyo, H., Morimoto, B., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94364-5 · Cited by 45
Peptide-Based Complex Coacervates Stabilized by Cation−π Interactions for Cell Engineering
Sun, Y., Wu, X. J., Li, J., Verma, C. S., Yu, J., & Miserez, A. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c14469 · Cited by 56
Guidara, C. L., Adamo, R., Sala, C., & Micoli, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105487 · Cited by 57
Vaccine escape in a heterogeneous population: insights for SARS-CoV-2 from a simple model
Gog, J. R., Hill, E. M., Danon, L., & Thompson, R. N. (2021) · Royal Society Open Science · doi:10.1098/rsos.210530 · Cited by 54
Ligand-mediated delivery of RNAi-based therapeutics for the treatment of oncological diseases
Abdelaal, A. M., & Kasinski, A. L. (2021) · NAR Cancer · doi:10.1093/narcan/zcab030 · Cited by 48
SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responses
Puhach, O., Bellon, M., Adea, K., Bekliz, M., Hosszu-Fellous, K., Sattonnet‐Roche, P., Coudurier-Boeuf, S., Arm‐Vernez, I., Kaiser, L., Eckerle, I., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104893 · Cited by 41
Wang, X., Mahmood, S. F., Jin, F., Cheah, W. K., Ahmad, M., Sohail, M. A., Ahmad, W., Suppan, V. K. L., Sayeed, M. A., Luxmi, S., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2088406 · Cited by 44
Self-citationSerious complications of COVID-19 vaccines: A mini-review
Fragkou, P. C., & Dimopoulou, D. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100145 · Cited by 43
Sönmezer, M. Ç., Şahin, T. K., Erul, E., Ceylan, F., Hamurcu, M. Y., Morova, N., Al, I. R., & Ünal, S. (2022) · Vaccines · doi:10.3390/vaccines10020278 · Cited by 49
Lang, R., Humes, E., Coburn, S. B., Horberg, M. A., Fathi, L., Watson, E. S., Jefferson, C. R., Park, L. S., Gordon, K. S., Akgün, K. M., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.36397 · Cited by 47
Chen, Z., Yang, Y., Qiu, X., Zhou, H., Wang, R., & Xiong, H. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c14500 · Cited by 48
Self-citationKappelman, M. D., Weaver, K. N., Zhang, X., Dai, X., Watkins, R. D., Adler, J., Dubinsky, M. C., Kastl, A., Bousvaros, A., Strople, J. A., et al. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001619 · Cited by 44
Corbett, K. S., Nason, M. C., Flach, B., Gagne, M., O’ Connell, S., Johnston, T. S., Shah, S. N., Edara, V. V., Floyd, K., Lai, L., et al. (2021) · doi:10.1101/2021.04.20.440647 · Cited by 43
Self-citationFollmann, D. A., O’Brien, M. P., Fintzi, J., Fay, M. P., Montefiori, D. C., Mateja, A., Herman, G. A., Hooper, A. T., Turner, K. C., Chan, K.-C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39292-w · Cited by 41
Self-citationBrook, B., Duval, V., Barman, S., Speciner, L., Sweitzer, C., Khanmohammed, A., Menon, M., Foster, K., Ghosh, P., Abedi, K., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adm8451 · Cited by 52
Self-citationBlood Pressure Increase following COVID-19 Vaccination: A Systematic Overview and Meta-Analysis
Angeli, F., Reboldi, G., Trapasso, M., Santilli, G., Zappa, M., & Verdecchia, P. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9050150 · Cited by 51
COVID-19 vaccination in patients with immune thrombocytopenia
Visser, C., Swinkels, M., van Werkhoven, E. D., Croles, F. N., Noordzij-Nooteboom, H. S., Eefting, M., Last-Koopmans, S. M., Idink, C., Westerweel, P. E., Santbergen, B., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021006379 · Cited by 41
Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases
Kronbichler, A., Anders, H., Juarez, G. M. F., Floege, J., Goumenos, D. S., Segelmark, M., Tesař, V., Türkmen, K., van Kooten, C., & Bruchfeld, A. N. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab064 · Cited by 50
Jung, O., Jung, H., Thủy, L. T. T., Choi, M., Kim, S., Jeon, H., Yang, J., Kim, S., Kim, T., Lee, E., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202303857 · Cited by 48
Lamacchia, G., Mazzoni, A., Spinicci, M., Vanni, A., Salvati, L., Peruzzi, B., Bencini, S., Capone, M., Carnasciali, A., Farahvachi, P., et al. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01325-2 · Cited by 44
SARS‐CoV‐2 vaccination in solid‐organ transplant recipients: What the clinician needs to know
Giannella, M., Pierrotti, L. C., Helanterä, I., & Manuel, O. (2021) · Transplant International · doi:10.1111/tri.14029 · Cited by 43
Lipid Nanoparticle-Based Delivery SystemA Competing Place for mRNA Vaccines
Zhang, X., Li, Y., & Zhou, Z. (2024) · ACS Omega · doi:10.1021/acsomega.3c08353 · Cited by 45
Shi, R., Liu, X., Wang, Y., Pan, M., Wang, S., Shi, L., & Ni, B. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2342592 · Cited by 56
Review of the COVID-19 Risk in Multiple Sclerosis
Chaudhry, F., Jageka, C., Levy, P. D., Cerghet, M., & Lisak, R. P. (2021) · Journal of Cellular Immunology · doi:10.33696/immunology.3.080 · Cited by 44
Individual costs and societal benefits of interventions during the COVID-19 pandemic
Traulsen, A., Levin, S. A., & Saad-Roy, C. M. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303546120 · Cited by 55
An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma
Deng, Z., Yang, H., Tian, Y., Liu, Z., Sun, F., & Yang, P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.975408 · Cited by 49
RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases
Bejar, N., Tat, T. T., & Kiss, D. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01007-9 · Cited by 46
Pharmacological Treatment of Secondary Lymphedema
Brown, S., Dayan, J. H., Coriddi, M. R., Campbell, A.-C., Kuonqui, K. G., Shin, J., Park, H. J., Mehrara, B. J., & Kataru, R. P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.828513 · Cited by 47
Benkeser, D. C., Montefiori, D. C., McDermott, A. B., Fong, Y., Janes, H., Deng, W., Zhou, H., Houchens, C. R., Martins, K. A. O., Jayashankar, L., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.ade9078 · Cited by 51
Self-citationEftekhari, Z., Zohrabi, H., Oghalaie, A., Ebrahimi, T., Shariati, F. S., Behdani, M., & Kazemi‐Lomedasht, F. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102313 · Cited by 52
Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada
VILCHES, T. N., Zhang, K., Exan, R. V., Langley, J. M., & Moghadas, S. M. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.058 · Cited by 48
Liposome-Based Carriers for CRISPR Genome Editing
Yin, X., Harmancey, R., McPherson, D. D., Kim, H., & Huang, S. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612844 · Cited by 46
Antibiotic resistance during and beyond COVID-19
Livermore, D. M. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlab052 · Cited by 51
Advances in CAR‐Engineered Immune Cell Generation: Engineering Approaches and Sourcing Strategies
Chen, Z., Hu, Y., & Mei, H. (2023) · Advanced Science · doi:10.1002/advs.202303215 · Cited by 52
Prophylactic vaccine delivery systems against epidemic infectious diseases
Pan, C., Yue, H., Zhu, L., Ma, G., & Wang, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113867 · Cited by 47
COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective
Marcelin, J. R., Pettifor, A. E., Janes, H., Brown, E. R., Kublin, J. G., & Stephenson, K. E. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac124 · Cited by 45
Self-citationTomalka, J. A., Suthar, M. S., Deeks, S. G., & Sékaly, R. (2022) · Nature Immunology · doi:10.1038/s41590-022-01130-4 · Cited by 47
Prasad, A., Hurlburt, G. A., Podury, S., Tandon, M., Kingree, S., & Sriwastava, S. (2021) · Neurology International · doi:10.3390/neurolint13030040 · Cited by 46
Alwani, S., Wasan, E. K., & Badea, I. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00128 · Cited by 49
Pawlowski, C., Rincón-Hekking, J., Awasthi, S., Pandey, V., Lenehan, P. J., Venkatakrishnan, A., Bade, S., O’Horo, J. C., Virk, A., Swift, M. D., et al. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.105923 · Cited by 42
New-onset IgA nephropathy following COVID-19 vaccination
Ma, Y., & Xu, G. (2022) · QJM · doi:10.1093/qjmed/hcac185 · Cited by 46
Hyperglycemic Emergencies Associated With COVID-19 Vaccination: A Case Series and Discussion
Lee, H. J., Sajan, A., & Tomer, Y. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab141 · Cited by 44
Burn, E., Li, X., Kostka, K., Stewart, H. M., Reich, C., Seager, S., Duarte‐Salles, T., Fernandez‐Bertolin, S., Aragón, M., Reyes, C., et al. (2022) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5419 · Cited by 43
Haroz, E. E., Kemp, C. G., O’Keefe, V. M., Pocock, K., Wilson, D. R., Christensen, L., Walls, M. L., Barlow, A., & Hammitt, L. L. (2022) · American Journal of Public Health · doi:10.2105/ajph.2021.306635 · Cited by 49
Mades, A., Chellamathu, P., Kojima, N., Lopez, L., MacMullan, M. A., Denny, N., Angel, A. N., Santacruz, M., Casian, J. G., Brobeck, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-03931-3 · Cited by 42
Gardner, B. J., & Kilpatrick, A. M. (2024) · Viruses · doi:10.3390/v16030479 · Cited by 49
Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S. Y., Gasser, R., Beaudoin-Bussières, G., Brassard, N., Laumaea, A., Vézina, D., Prévost, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.18.435972 · Cited by 42
Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment
Karim, M. E., Haque, S. T., Al-Busaidi, H., Bakhtiar, A., Tha, K. K., Holl, M. M. B., & Chowdhury, E. H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01418-x · Cited by 47
Postvaccination SARS‐CoV‐2 infection among healthcare workers: A systematic review and meta‐analysis
Chandan, S., Khan, S. R., Deliwala, S., Mohan, B., Ramai, D., Chandan, O. C., & Facciorusso, A. (2021) · medRxiv · doi:10.1002/jmv.27457 · Cited by 28
Kapoor, K. S., Harris, K., Arian, K. A., Ma, L., Zancanela, B. S., Church, K. A., McAndrews, K. M., & Kalluri, R. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.08.002 · Cited by 59
Wang, Y., Duan, L., Li, M., Wang, J., Yang, J., Song, C., Li, J., Wang, J., Jia, J., & Xu, J. (2022) · Vaccines · doi:10.3390/vaccines10010129 · Cited by 42
Loh, J. S., Tan, L., Lee, W.-L., Ming, L. C., How, C. W., Foo, J. B., Kifli, N., Goh, B. H., & Ong, Y. S. (2021) · Cancers · doi:10.3390/cancers13215346 · Cited by 47
Quer, G., Gadaleta, M., Radin, J. M., Andersen, K. G., Baca-Motes, K., Ramos, E., Topol, E. J., & Steinhubl, S. R. (2022) · npj Digital Medicine · doi:10.1038/s41746-022-00591-z · Cited by 43
N1-methyl-pseudouridine is incorporated with higher fidelity than pseudouridine in synthetic RNAs
Chen, T.-H., Potapov, V., Dai, N., Ong, J. L., & Roy, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-17249-1 · Cited by 49
Wallace, M. M., Moulia, D., Blain, A. E., Ricketts, E. K., Minhaj, F. S., Link‐Gelles, R., Curran, K. G., Hadler, S. C., Asif, A., Godfrey, M., et al. (2011) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7111a4 · Cited by 42
The promise and perils of immunotherapy
Lesch, S., & Gill, S. I. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004453c · Cited by 47
Domenico, L. D., Sabbatini, C. E., Boëlle, P., Poletto, C., Crépey, P., Paireau, J., Cauchemez, S., Beck, F., Noël, H., Lévy-Bruhl, D., et al. (2021) · Communications Medicine · doi:10.1038/s43856-021-00057-5 · Cited by 51
Huang, X., Yan, Y., Su, B., Xiao, D., Yu, M., Jin, X., Duan, J., Zhang, X., Zheng, S., Fang, Y., et al. (2021) · Viruses · doi:10.3390/v14020277 · Cited by 42
Perceptions of the COVID-19 vaccine Among Patients With Cancer: A Single-Institution Survey
Moujaess, E., Zeid, N. B., Samaha, R., Sawan, J., Kourié, H. R., Labaki, C., Chebel, R., Chahine, G. Y., Karak, F. E., Nasr, F. L., et al. (2021) · Future Oncology · doi:10.2217/fon-2021-0265 · Cited by 50
Vitamins, supplements and COVID-19: a review of currently available evidence
Speakman, L., Michienzi, S. M., & Badowski, M. E. (2021) · Drugs in Context · doi:10.7573/dic.2021-6-2 · Cited by 51
Protein-based nanoparticles for therapeutic nucleic acid delivery
Eweje, F., Walsh, M. L., Ahmad, K., Ibrahim, V., Alrefai, A., Chen, J., & Chaikof, E. L. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2023.122464 · Cited by 47
Fusco, M. D., Marczell, K., Deger, K. A., Moran, M. M., Wiemken, T. L., Cane, A. D., de Boisvilliers, S., Yang, J., Vaghela, S., & Roïz, J. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2071427 · Cited by 46
Streinu‐Cercel, A., Săndulescu, O., Preoțescu, L., Kim, J. Y., Ys, K., Cheon, S., Jang, Y. R., Lee, S. J., Kim, S. H., Chang, I., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac053 · Cited by 49
Tailoring biomaterials for vaccine delivery
Zhuo, Y., Zeng, H., Su, C., Lv, Q., Cheng, T., & Lei, L. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02758-0 · Cited by 53
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity
Jaycox, J. R., Lucas, C. G. D. O., Yildirim, I. B., Dai, Y., Wang, E. Y., Monteiro, V. S., Lord, S. M., Carlin, J. S., Kita, M., Buckner, J. H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36686-8 · Cited by 48
Aptamers targeting amyloidogenic proteins and their emerging role in neurodegenerative diseases
Murakami, K., Izuo, N., & Bitan, G. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101478 · Cited by 45
Transfection Potency of Lipid Nanoparticles Containing mRNA Depends on Relative Loading Levels
Liao, S., Wang, S., Wadhwa, A., Birkenshaw, A., Fox, K., Cheng, M. H. Y., Casmil, I. C., Magaña, A. A., Bathula, N. V., Ho, C.-H., et al. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c20077 · Cited by 50
Ma, Y., & Fenton, O. S. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c02584 · Cited by 45
Buchy, P., Buisson, Y., Cintra, O. A. L., Dwyer, D. E., Nissen, M. D., de Lejarazu, R. O., & Petersen, E. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.045 · Cited by 51
Ahmed, S., Khan, S., Imran, I., Mughairbi, F. A., Sheikh, F. S., Hussain, J., Khan, A., & Al‐Harrasi, A. (2021) · Vaccines · doi:10.3390/vaccines9080836 · Cited by 45
Chen, Y., Lin, Y., Chang, Y., Chou, W., & Yen, C. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18137042 · Cited by 51
Landscape and progress of global COVID-19 vaccine development
Huang, H., Wang, S., Tang, Y., Sheng, W., Zuo, C., Wu, D., Fang, H., Du, Q., & Li, N. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1945901 · Cited by 46
COVID-19 Vaccination in Korea: Past, Present, and the Way Forward
Nham, E., Song, J. Y., Noh, J. Y., Cheong, H. J., & Kim, W. J. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e351 · Cited by 45
The Impact of the COVID-19 Vaccine Distribution on Mental Health Outcomes
Agrawal, V., Cantor, J., Sood, N., & Whaley, C. (2021) · National Bureau of Economic Research · doi:10.3386/w29593 · Cited by 45
D’Offizi, G., Agrati, C., Comandini, U. V., Castilletti, C., Puro, V., Piccolo, P., Montalbano, M., Meschi, S., Tartaglia, E., Sorace, C., et al. (2021) · Liver International · doi:10.1111/liv.15089 · Cited by 46
Butler, M., Coebergh, J. A., Safavi, F., Carson, A. J., Hallett, M., Michael, B. D., Pollak, T. A., Solomon, T., Stone, J., Nicholson, T. R., et al. (2021) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.21050116 · Cited by 42
Immunologic response of mRNA SARS-CoV-2 vaccination in adolescent kidney transplant recipients
Crane, C. R., Phebus, E., & Ingulli, E. G. (2021) · Pediatric Nephrology · doi:10.1007/s00467-021-05256-9 · Cited by 43
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.